Ymmunobio AG, a preclinical stage biotech company specializing in the development of CEACAM (carcinoembryonic antigen-related cell adhesion molecules) antibodies as anti-cancer treatments, will present pre-clinical data that shows the anti-cancer activity of its lead asset YB-200 at the 37th annual meeting of the Society for Immunotherapy of Cancer (SITC) in Boston, MA, and virtually on November 8-12, 2022.
TITLE: Novel, immune agonistic CEACAM1/5 antibody (YB-200) demonstrates anti-tumor efficacy and significantly increases B-cell response in syngeneic liver Hepa1-6 tumor microenvironment.
POSTER NUMBER: 1384
PRESENTERS: Dr. Katrin Rupalla, CEO, Ymmunobio AG, and Dr. Bernhard B. Singer, University Essen/Duisburg, Germany
DATE/TIME: Friday, November 11, 2022. Posters will be on display in Hall C from 9 a.m. to 9 p.m. EST. The full text of this year’s SITC abstracts will be published in the Journal for ImmunoTherapy of Cancer (JITC) as a supplement at 8:00 a.m. EST on Tuesday, Nov. 7, 2022 and available from the SITC website.
Co-authors of Ymmunobio’s poster presentation are Michel Janicot, PhD, Ymmunobio, Alexej Schmidt, PhD, University of Umea, Sweden, and Iris Helfrich, PhD, Professor at the University of Munich, Germany.
Investor Relations: Dr. Katrin Rupalla, [email protected]
Ymmunobio AG is a preclinical stage oncology biotech company developing a novel class of CEACAM antibodies to treat cancer. Ymmunobio’s wholly owned CEACAM antibodies directly target immune cell communication, thereby increasing the efficiency of the immune system to fight cancer. Learn more on Ymmunobio’s website and follow on LinkedIn.